Lowers the risk of cardiovascular death and hospitalization for heart failure. ANDA 213668, held by Hetero Labs Ltd Iii. Sacubitril; Valsartan.
As of Nov 21, 2026, ANDA 213668 (Sacubitril and Valsartan), held by Hetero Labs Ltd Iii, was first approved by FDA on Jul 17, 2025, with 0 approved supplements and 0 published complete response letters.
Sacubitril and valsartan tablets are a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 17, 2025 | Original application | Approved | None posted |
| Sacubitril and Valsartan24MG;26MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan49MG;51MG · tablet;oral | Sacubitril; Valsartan | Rx |
| Sacubitril and Valsartan97MG;103MG · tablet;oral | Sacubitril; Valsartan | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters